Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 5Brain Neoplasms 5Neoplasm Metastasis 2Small Cell Lung Carcinoma 1Radiation Injuries 1Neurotoxicity Syndromes 1Neoplasms 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Fatigue 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Mental Status and Dementia Tests × Clear all
NCT01217411 2024-11-19

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
5 enrolled 6 charts
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡